Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Qishenyiqi Dripping Pills in Healthy Participants
NCT04471298Phase 1Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of qishen yiqi dripping pills in coronary heart disease (CHD) and angina pectoris (6 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Adverse events, Number of participants with abnormal vital signs index (body temperature) and 10 more. Started Sep 2020; status: completed.
02
Drugs
qishen yiqi dripping pills
03
Conditions
coronary heart disease (CHD)angina pectoris
Beyond the preview
Go deeper on NCT04471298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471298.